Organon interim CEO granted 333,889 RSUs, exercises awards
Organon & Co. interim CEO Joseph T. Morrissey Jr. reported compensation-related equity activity in Organon stock.
Rhea-AI Filing Summary
Organon & Co. interim CEO Joseph T. Morrissey Jr. reported compensation-related equity activity in Organon stock. On March 31, 2026, he received a grant of 333,889 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
He also exercised previously granted RSUs into common stock and had shares withheld to cover tax obligations. In total, 24,584 RSUs were converted into common stock, with 7,005 shares withheld at $5.70 per share for taxes. Following these transactions, he directly holds 123,122.923 shares of Organon common stock and 333,889 RSUs subject to future vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
24,584 shares exercised/converted
Exercise
7 txns
Insider
Morrissey Joseph T. Jr.
Role
Interim CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 333,889 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 7,795 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 16,789 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,795 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 2,221 | $5.70 | $13K |
| Exercise | Common Stock | 16,789 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 4,784 | $5.70 | $27K |
Holdings After Transaction:
Restricted Stock Units — 367,469 contracts (Direct);
Common Stock — 123,122.923 shares (Direct)
Footnotes (5)
- F1. This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
- F2. On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
- F3. Each RSU represents a contingent right to receive one share of Organon common stock.
- F4. On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
- F5. On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Key Figures
New RSU grant: 333,889 RSUs
RSUs exercised: 24,584 RSUs
Tax withholding shares: 7,005 shares
+3 more
6 metrics
New RSU grant
333,889 RSUs
Granted to interim CEO on March 31, 2026
RSUs exercised
24,584 RSUs
Converted into common stock on March 31, 2026
Tax withholding shares
7,005 shares
Withheld to cover tax obligations at $5.70 per share
Tax withholding price
$5.70 per share
Price used for tax-related share withholding
Shares held after transactions
123,122.923 shares
Direct Organon common stock holdings post-transaction
Unvested RSUs outstanding
333,889 RSUs
Remain subject to vesting in 2027, 2028, and 2029
Key Terms
Restricted Stock Units, contingent right, vest, tax liability, +1 more
5 terms
Restricted Stock Units financial
"On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each RSU represents a contingent right to receive one share of Organon common stock"
vest financial
"These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
tax liability financial
"Payment of exercise price or tax liability by delivering securities"
exercise or conversion of derivative security financial
"Exercise or conversion of derivative security"
FAQ
What equity compensation did Organon (OGN) interim CEO Joseph Morrissey receive?
Joseph T. Morrissey Jr. received a grant of 333,889 Restricted Stock Units (RSUs) on March 31, 2026. Each RSU represents a contingent right to receive one share of Organon common stock, subject to future vesting conditions and service requirements described in the award terms.
How do the new RSUs for Organon (OGN) interim CEO vest over time?
The 333,889 RSUs granted to Joseph T. Morrissey Jr. vest in three equal installments. They become exercisable on March 31, 2027, March 31, 2028, and March 31, 2029, creating a multi‑year incentive structure tied to his continued service with Organon.
What RSU exercises and tax withholdings were reported for Organon (OGN) interim CEO?
On March 31, 2026, 24,584 RSUs previously granted to Joseph T. Morrissey Jr. were exercised into common stock. To cover tax obligations, 7,005 shares of common stock were withheld at a price of $5.70 per share, a non‑market, tax‑related disposition.
Were the Organon (OGN) RSUs tied to a specific stock price at grant?
The RSUs granted on March 31, 2026 were awarded using $5.70, the closing market price of Organon common stock on March 30, 2026, as required under the applicable plan. This price serves as the reference value for the equity award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
